Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.71 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.67 |
| ▸ | PGR | P06401 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.67 |
| ▸ | AR | P10275 | 2/20 | 0.67 |
| ▸ | TNF | P01375 | 1/20 | 0.67 |
| ▸ | IL6 | P05231 | 1/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.67 |
| ▸ | GLUL | P15104 | 1/20 | 0.67 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednival SCHEMBL25388 | 1.00 | HIF1A (0.73) | HIF1AKMT2ANR3C2NR3C1PGR | |
| Prednival SCHEMBL2966209 | 1.00 | HIF1A (0.73) | HIF1AKMT2ANR3C2NR3C1PGR | |
| Prednival SCHEMBL11585728 | 1.00 | HIF1A (0.73) | HIF1AKMT2ANR3C2NR3C1PGR | |
| Prednival SCHEMBL25387 | 1.00 | HIF1A (0.73) | HIF1AKMT2ANR3C2NR3C1PGR | |
| SCHEMBL7984 | 0.98 | NR3C2 (0.74) | HIF1AKMT2ANR3C2NR3C1PGR | |
| SCHEMBL7142733 | 0.98 | NR3C2 (0.74) | HIF1AKMT2ANR3C2NR3C1PGR | |
| SCHEMBL7613014 | 0.98 | NR3C2 (0.74) | HIF1AKMT2ANR3C2NR3C1PGR | |
| SCHEMBL7145314 | 0.98 | NR3C2 (0.74) | HIF1AKMT2ANR3C2NR3C1PGR | |
| SCHEMBL11016342 | 0.96 | NR3C2 (0.72) | HIF1AKMT2ANR3C2NR3C1PGR | |
| SCHEMBL6857090 | 0.96 | NR3C2 (0.72) | HIF1AKMT2ANR3C2NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2026818-B1 | COMBINATION OF STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7776846-B2 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2010-08-17 | — | — | US | disclosed |
| US-7691811-B2 | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye | BODOR LABORATORIES, INC. | 2010-04-06 | — | — | US | disclosed |
| US-7687484-B2 | Enhancing the activity and/or duration of action of soft anti-inflammatory steroids such as loteprednol etabonate with a synergistic amount of another steroid such as cortisone | BODOR LABORATORIES, INC. | 2010-03-30 | — | — | US | disclosed |
| EP-2026818-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | Bodor, Nicholas S. (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080261930-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR LABORATORIES, INC. | 2008-10-23 | — | — | US | disclosed |
| US-7419971-B2 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2008-09-02 | — | — | US | disclosed |
| US-20080194468-A1 | TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE | BODOR LABORATORIES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | BODOR LABORATORIES, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007142842-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1658083-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR, Nicholas S. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050020551-A1 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004112800-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR NICHOLAS S (US) | 2004-12-29 | — | — | WO | disclosed |
| US-6835724-B2 | Topical antiinflammatory agents for treating inflammatory dermatoses | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-28 | — | — | US | disclosed |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-01 | — | — | US | disclosed |
| US-4918065-A | ANTIINFLAMMATORY AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-04-17 | — | — | US | disclosed |
| US-4655971-A | USING AN ANHYDRIDE AND ACID CATALYST TO ESTERIFY HYDROXY'S IN THE 17- OR 17- AND 21-POSITION; ENHANCED ANTIINFLAMMATORY AGENTS | PLURICHEMIE ANSTALT (LI) | 1987-04-07 | — | — | US | disclosed |
| EP-0072200-B1 | STEROIDAL ESTERS AND PROCESS FOR THE PREPARATION OF STEROIDAL ESTERS | PLURICHEMIE ANSTALT (LI) | 1985-11-21 | — | — | EP | disclosed |
| EP-0072200-A2 | Steroidal esters and process for the preparation of steroidal esters | PLURICHEMIE ANSTALT (LI) | 1983-02-16 | — | — | EP | disclosed |
| US-3998701-A | Process for the preparation of 17-acyl esters of 17α, 21-dihydroxysteroids of the pregnane series and novel products | LARK S.P.A. (IT) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194468-A1 | TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE | HSD3B1, HSD3B2, HSD11B1 | HIF1A 1047/4885KMT2A 4078/4885NR3C2 65/4885 |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | HSD3B1, HSD11B1, EBP | HIF1A 1372/4885KMT2A 4326/4885NR3C2 9/4885 |
| US-20050020551-A1 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | NR3C1, NR3C2, HSD17B7 | HIF1A 1389/4885KMT2A 4222/4885NR3C2 2/4885 |
| US-20080261930-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | NR3C1, NR3C2, HSD17B7 | HIF1A 1389/4885KMT2A 4222/4885NR3C2 2/4885 |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | NR3C1, HSD3B1, HSD17B7 | HIF1A 2813/4885KMT2A 2472/4885NR3C2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.